Peer Review File

Article information: https://dx.doi.org/10.21037/tbcr-23-33

Reviewer Comments

Comment 1: Authors report and expert consensus on the use, efficacy and safety of toripalimab plus nab-paclitaxel as first- or second-line in women with advanced triple negative breast cancer. There are some English mistakes which need to be corrected. Furthermore, authors should write a small paragraph on the possibile limitation of such report.

Reply 1: We have supplied the paragraph on the possibile limitation before the conclusion of the article.

The main purpose of this report is to describe the key points of the design background of the TORCHLIGHT trial, therefore, the explanation of the entire trial may not be comprehensive enough.In addition, we reviewed the primary clinical research on the application of immune checkpoint inhibitors in advanced triple negative breast cancer both domestically and internationally from the perspective of clinical trial design.The content involves the PD-1 or PD-L1 inhibitor single agent therapy in the initial stage, as well as PD-1 or PD-L1 inhibitor in combination with other drugs in recent.Based on the investigational drug toripalimab of TORCHLIGHT trial, we briefly reviewed the clinical trials on other domestic immune checkpoint inhibitors combination therapy during the same period,which have significant differences in trial design compared to TORCHLIGHT trial, especially for drugs used in combination, most of which choose chemotherapy free regimen.At the same time, we summarized the main clinical trials in the combined treatment of immune checkpoint inhibitor and chemotherapy abroad, from phase Ib/II trials to phase III trials.Due to only focusing on combination chemotherapy, the review content is limited and the number of research items included is also relatively limited, which is the limitation of the report.